
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
As policy makers struggle to devise a pharmacy benefit for Medicare patients, pressure mounts to impose spending limits on medications. In turn, consumer activists are challenging industry’s longtime claim that price controls will reduce investment in R&D for life-saving therapies.
about 25 years ago
New Playing Fieldsabout 25 years ago
Inefficiencies: Cutting Through the Jungleabout 25 years ago
Legislation: EC Proposes Changesabout 25 years ago
Flexing Their Budgets: Big Pharma Spend Trendsabout 25 years ago
Media Mix Town Meeting 2001: Much Ado About Media





